Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risankizumab - AbbVie/Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Risankizumab - AbbVie/Boehringer Ingelheim

Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZI

Latest Information Update: 30 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Registered Erythrodermic psoriasis; Generalised pustular psoriasis; Ulcerative colitis
  • Phase III Palmoplantar pustulosis
  • Phase II Atopic dermatitis; Hidradenitis suppurativa
  • No development reported Unspecified
  • Discontinued Ankylosing spondylitis; Asthma

Most Recent Events

  • 26 Aug 2024 AbbVie plans a phase I pharmacokinetics trial for Healthy volunteers in September 2024 (SC, Injection) (NCT06571266)
  • 26 Jul 2024 Registered for Ulcerative colitis (In adolescents, In the elderly, In adults) in Norway, Norway, Liechtenstein, Iceland, European Union (IV)
  • 23 Jul 2024 Abbvie initiates enrolment in a phase I pharmacokinetics trial(In volunteers) in USA (IV)(SC) (NCT06487572)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top